↓ Skip to main content

Targeted therapies for diarrhea-predominant irritable bowel syndrome

Overview of attention for article published in Clinical and Experimental Gastroenterology, May 2012
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)

Mentioned by

patent
1 patent
facebook
1 Facebook page

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
54 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Targeted therapies for diarrhea-predominant irritable bowel syndrome
Published in
Clinical and Experimental Gastroenterology, May 2012
DOI 10.2147/ceg.s29023
Pubmed ID
Authors

Kevin W Olden

Abstract

Irritable bowel syndrome (IBS) causes gastrointestinal symptoms such as abdominal pain, bloating, and bowel pattern abnormalities, which compromise patients' daily functioning. Common therapies address one or two IBS symptoms, while others offer wider symptom control, presumably by targeting pathophysiologic mechanisms of IBS. The aim of this targeted literature review was to capture clinical trial reports of agents receiving the highest recommendation (Grade 1) for treatment of IBS from the 2009 American College of Gastroenterology IBS Task Force, with an emphasis on diarrhea-predominant IBS. Literature searches in PubMed captured articles detailing randomized placebo-controlled trials in IBS/diarrhea-predominant IBS for agents receiving Grade I (strong) 2009 American College of Gastroenterology IBS Task Force recommendations: tricyclic antidepressants, nonabsorbable antibiotics, and the 5-HT(3) receptor antagonist alosetron. Studies specific for constipation-predominant IBS were excluded. Tricyclic antidepressants appear to improve global IBS symptoms but have variable effects on abdominal pain and uncertain tolerability; effects on stool consistency, frequency, and urgency were not adequately assessed. Nonabsorbable antibiotics show positive effects on global symptoms, abdominal pain, bloating, and stool consistency but may be most efficacious in patients with altered intestinal microbiota. Alosetron improves global symptoms and abdominal pain and normalizes bowel irregularities, including stool frequency, consistency, and fecal urgency. Both the nonabsorbable antibiotic rifaximin and the 5-HT(3) receptor antagonist alosetron improve quality of life. Targeted therapies provide more complete relief of IBS symptoms than conventional agents. Familiarization with the quantity and quality of evidence of effectiveness can facilitate more individualized treatment plans for patients with this heterogeneous disorder.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Philippines 1 2%
Denmark 1 2%
France 1 2%
Unknown 50 93%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 19%
Student > Ph. D. Student 8 15%
Researcher 7 13%
Student > Bachelor 5 9%
Professor > Associate Professor 5 9%
Other 11 20%
Unknown 8 15%
Readers by discipline Count As %
Medicine and Dentistry 24 44%
Agricultural and Biological Sciences 9 17%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Biochemistry, Genetics and Molecular Biology 3 6%
Psychology 3 6%
Other 3 6%
Unknown 8 15%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 September 2016.
All research outputs
#7,178,663
of 22,691,736 outputs
Outputs from Clinical and Experimental Gastroenterology
#105
of 306 outputs
Outputs of similar age
#67,841
of 244,134 outputs
Outputs of similar age from Clinical and Experimental Gastroenterology
#2
of 4 outputs
Altmetric has tracked 22,691,736 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 306 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.6. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 244,134 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.